Rabab Gaafar
YOU?
Author Swipe
View article: Monoclonal Gammopathy of Rheumatologic Significance (MGRhS): a systemic vision of clonal disorders with multiple organ involvement
Monoclonal Gammopathy of Rheumatologic Significance (MGRhS): a systemic vision of clonal disorders with multiple organ involvement Open
View article: Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Open
PURPOSE A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor–…
View article: 84P The predictive and prognostic value of tumor infiltrating lymphocytes in advanced non-small cell lung cancer
84P The predictive and prognostic value of tumor infiltrating lymphocytes in advanced non-small cell lung cancer Open
Recent studies suggest immune infiltrates in primary tumors and metastases can serve as independent prognostic biomarkers and predict efficacy of platinum-based anticancer drugs in patients with non-small cell lung cancer patients (NSCLC).…
View article: Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus
Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus Open
Purpose The theme of the St. Gallen International Breast Cancer Conference 2021 held virtually for the first time, due to the COVID-19 pandemic, was on tailoring therapies for patients with early breast cancer. A monkey survey that include…
View article: Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients
Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients Open
View article: Pain control post IMRT for malignant pleural mesothelioma
Pain control post IMRT for malignant pleural mesothelioma Open
Purpose: This is retrospective study-reviewing patients with unresectable pleural mesothelioma who received IMRT as part of their treatment course. This work aimed to study pain control and improvement among this group of patients. Methods…
View article: Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa
Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa Open
PURPOSE Anaplastic lymphoma kinase ( ALK) gene alterations are potent oncogenic drivers in non–small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% of …
View article: Breast cancer in Egypt:a review of disease presentation and detection strategies
Breast cancer in Egypt:a review of disease presentation and detection strategies Open
Carcinoma of the breast is the most prevalent cancer among Egyptian women and constitutes 29% of National Cancer Institute cases. Median age at diagnosis is one decade younger than in countries of Europe and North America and most patients…
View article: Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication Open
View article: Supplementary Material for: Hospital Accreditation: A Review of Evidence, Regulatory Compliance, and Healthcare Outcome Measures
Supplementary Material for: Hospital Accreditation: A Review of Evidence, Regulatory Compliance, and Healthcare Outcome Measures Open
Background: Hospitals are increasingly under pressure to provide safe and high-quality care at an affordable cost. In response to this challenge, many have adopted accreditation as an internationally recognized tool to facili…
View article: Risk factors for inflammatory and non-inflammatory breast cancer in North Africa
Risk factors for inflammatory and non-inflammatory breast cancer in North Africa Open
View article: P-13 Current and expected future profile changes of gastric and pancreatic cancer patients at presentation
P-13 Current and expected future profile changes of gastric and pancreatic cancer patients at presentation Open
View article: Effects of Cancer, Coronary Artery Disease and other Comorbidities on COVID-19 Related Mortality: A Meta-analysis and Meta-regression
Effects of Cancer, Coronary Artery Disease and other Comorbidities on COVID-19 Related Mortality: A Meta-analysis and Meta-regression Open
Objective: To investigate Coronavirus Disease 2019 (COVID-19) associated mortality, the prevalence of different symptoms, and the prevalence and association between comorbidities and their effects on outcomes. Methods: We performed a syste…
View article: Lung Cancer in the Middle East and North Africa Region
Lung Cancer in the Middle East and North Africa Region Open
View article: P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma Open
View article: Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common <i>EGFR</i> Mutations, After Chemotherapy: a Phase IV Study
Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common <i>EGFR</i> Mutations, After Chemotherapy: a Phase IV Study Open
Our data support the use of afatinib (40 mg/day) as an effective and well-tolerated second-line treatment in EGFRm+ NSCLC.
View article: Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa Open
View article: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) Open
View article: PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial
PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial Open
View article: 157P Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study
157P Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study Open
View article: Contributing factors to the outcome of primary malignant chest wall tumors
Contributing factors to the outcome of primary malignant chest wall tumors Open
In primary malignant CWTs (PMCWTs) achievement of wide resection margins is of great importance to minimize the local tumor recurrence that will have an adverse impact on long-term survival.
View article: P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma Open
View article: PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma Open
View article: LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)
LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM) Open
View article: LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma Open
View article: P2.03b-054 Biomarker Predictors in NSCLC
P2.03b-054 Biomarker Predictors in NSCLC Open
View article: PUB071 Fragile-Site Associated Tumor Suppressor (FATS) Gene Expression Effect on the Sensitivity of Cisplatin and Gemcitabine in Advanced NSCLC
PUB071 Fragile-Site Associated Tumor Suppressor (FATS) Gene Expression Effect on the Sensitivity of Cisplatin and Gemcitabine in Advanced NSCLC Open
View article: ecancermedicalscience
ecancermedicalscience Open
Mistletoe preparation is an efficient and well tolerated sclerosant agent which needs further investigation.
View article: 162P: Molecular markers in advanced non small cell lung cancer patients receiving gemcitabine & cisplatin
162P: Molecular markers in advanced non small cell lung cancer patients receiving gemcitabine & cisplatin Open
View article: Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) Open